Insight

PTAB must bite bullet and make definitive call on hedge fund inter partes review requests

Inter partes review requests make up only a small part of the Patent Trial and Appeal Board’s workload; but they are causing it a major headache. That will continue for as long as it avoids addressing the issue head on

On September 1 the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) declined to institute a petition for the inter partes review of US Patent 8,399,514, owned by Biogen. It had been requested by the Coalition for Affordable Drugs, an organisation established by hedge fund investor Kyle Bass and IPNav founder Erich Spangenberg.

Want to read more?

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Straight talk on key IP issues, IAM aims to provide executive managers with the business perspective that often gets lost in technical jargon and legal details.

Gene Potkay
Senior vice president of intellectual property
The Nielsen Company

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?

Close

Register for more free content

  • Read more IAM blogs and articles
  • Receive the editor's weekly review by email
Register now  
Issue 90
;